Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

East Hills, New York Clinical Trials

A listing of East Hills, New York clinical trials actively recruiting patient volunteers.

RESULTS

Found (32) clinical trials

Safety and Tolerability of PF-05230907 in Intracerebral Hemorrhage

This study employs a modified continual reassessment method (mCRM) design to estimate the maximum tolerated dose (MTD) of PF-05230907, defined as a target toxicity rate of 15% based on treatment emergent thromboembolic and/or ischemic events (TIEs). The mCRM design utilizes Bayesian methodology to continuously learn the dose-toxicity relationship, which is ...

Phase

3.23 miles

Learn More »

The purpose of this research study is to investigate whether the trial product is effective and safe in reducing/managing weight in children. Winthrop-University Hospital Clinical Trials Center is seeking study participants (ages 7-11 years old), who have not started puberty to take part in this clinical research study because he/she ...

Phase

3.3 miles

Learn More »

Safety Tolerability and Pharmacokinetics of Multiple Rising Doses of Ixazomib in Lupus Nephritis

The drug being tested in this study is called ixazomib. Ixazomib is being tested to find a safe and well tolerated dose in participants with lupus nephritis. This study will look at side effects and lab results in participants who take ixazomib, along with the determination of the pharmacokinetics (PK). ...

Phase

3.8 miles

Learn More »

Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers

The primary objectives in the dose escalation phase are to evaluate safety and pharmacokinetics (PK) in order to determine the selected dose level(s) for expansion of REGN3767 as monotherapy and in combination with REGN2810 in patients with advanced malignancies, including lymphoma. The primary objectives in the dose expansion phase are ...

Phase

4.24 miles

Learn More »

Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

The purpose of this study is to evaluate the safety and efficacy of INCB050465 when combined with bendamustine and obinutuzumab in subjects with relapsed or refractory follicular lymphoma (FL).

Phase

4.24 miles

Learn More »

The purpose of this study is to evaluate the safety and tolerability of INCB050465 when combined with bendamustine and obinutuzumab in relapsed or refractory follicular lymphoma (FL).

Phase

4.24 miles

Learn More »

This is a clinical trial aimed to determine the best tolerated dosage of Cetuximab into arteries for the treatement of un-resectable recurrent head and neck cancer. Cetuximab belongs in a class of drugs called epidermal growth factor receptor (EGFR) inhibitors. A high percentage of head and neck cancers over-express EGFR. ...

Phase

4.24 miles

Learn More »

Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma

This is a single arm, pilot study designed to test the feasibility of using the CIVO (Comparative In Vivo Oncology) system in patients with soft tissue sarcoma accessible for percutaneous injection. Patients who are scheduled for surgical biopsy or tumor resection surgery will be injected one to three days prior ...

Phase

4.24 miles

Learn More »

A Phase I Study Of Etrolizumab Followed By Open-Label Extension And Safety Monitoring In Pediatric Patients With Moderate To Severe Ulcerative Colitis Or Moderate To Severe Crohn's Disease

This study will evaluate pharmacokinetics, pharmacodynamics and safety of etrolizumab in pediatric patients of 4 to <18 years of age with moderate to severe ulcerative colitis (UC) or with moderate to severe Crohn's disease (CD).

Phase

4.24 miles

Learn More »

A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors

An open-label, dose-escalation (Part 1), dose-expansion (Part 2) study to assess the safety, pharmacokinetics (PK), and preliminary efficacy of ABBV-155 alone and in combination with paclitaxel or docetaxel. In Part 1 (dose escalation), subjects will receive escalating doses of ABBV-155 monotherapy (Part 1a) or ABBV-155 in combination with paclitaxel or ...

Phase

4.41 miles

Learn More »